Enveda raised 845 million. George Petrocheilos of Catalio joined Enveda’s board.
Enveda uses its PRISM AI platform to discover drugs from plants and microbes. Three clinical-stage candidates include treatments for atopic dermatitis, post-GLP-1 weight maintenance, and inflammatory bowel disease. The company reported two positive early clinical readouts in 2026.
New investors include Durable Capital, ICONIQ, Lightspeed, Surveyor Capital (Citadel), T. Rowe Price, Digitalis Ventures, a sovereign wealth fund, and Alderline Group.